Pium Investment will make a 200 billion won investment in CHA Healthcare, a subsidiary of CHA Biotech.
CHA Biotech said on the 24th that it decided to sell 7,692,308 shares of CHA Healthcare that it holds to the Pium AI Future Healthcare fund. The total sale price is 200.08 billion won, with the per-share price set at 26,000 won.
The equity in CHA Healthcare that CHA Biotech is selling is about 43.5%, and with this investment, the Pium AI fund will immediately become the second-largest shareholder of CHA Healthcare. The Pium AI fund was established by Pium Invest, a subsidiary of Sugentech.
Regarding the reason for this equity sale, CHA Biotech said it is "to restructure the investor base by attracting new investors to CHA Healthcare."
The deal also includes a put option clause allowing the Pium AI fund to sell the CHA Healthcare equity back to CHA Biotech. If CHA Biotech breaches obligations related to stock disposal restrictions, tag-along rights, or the investor's prior consent rights, the Pium AI fund can request that its CHA Healthcare equity be repurchased.
CHA Healthcare is a hospital management company that operates more than 90 hospitals in seven countries, including the United States, Australia and Singapore. CHA Biotech is expanding as it prepares to list CHA Healthcare in 2027. At the end of last year, Cha Cares acquired Kakao Healthcare, and CHA Healthcare plans to merge its subsidiary Cha Cares by next year.